Cargando…
5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112590/ http://dx.doi.org/10.1097/01.HS9.0000928248.83702.ec |
| _version_ | 1785027654253019136 |
|---|---|
| author | Eleftheriou, P. Sharif, J. Kesse-Adu, R. Filian-Gloor, M. Agrawal, A. Barcelos, G. Telfer, P. |
| author_facet | Eleftheriou, P. Sharif, J. Kesse-Adu, R. Filian-Gloor, M. Agrawal, A. Barcelos, G. Telfer, P. |
| author_sort | Eleftheriou, P. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10112590 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101125902023-04-19 5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE Eleftheriou, P. Sharif, J. Kesse-Adu, R. Filian-Gloor, M. Agrawal, A. Barcelos, G. Telfer, P. Hemasphere Poster Presentations Lippincott Williams & Wilkins 2023-04-10 /pmc/articles/PMC10112590/ http://dx.doi.org/10.1097/01.HS9.0000928248.83702.ec Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Presentations Eleftheriou, P. Sharif, J. Kesse-Adu, R. Filian-Gloor, M. Agrawal, A. Barcelos, G. Telfer, P. 5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE |
| title | 5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE |
| title_full | 5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE |
| title_fullStr | 5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE |
| title_full_unstemmed | 5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE |
| title_short | 5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE |
| title_sort | 5613294 baseline patient characteristics from a uk early access to medicines scheme (eams) with voxelotor, a hbs polymerization inhibitor, for the treatment of hemolytic anemia due to sickle cell disease |
| topic | Poster Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112590/ http://dx.doi.org/10.1097/01.HS9.0000928248.83702.ec |
| work_keys_str_mv | AT eleftherioup 5613294baselinepatientcharacteristicsfromaukearlyaccesstomedicinesschemeeamswithvoxelotorahbspolymerizationinhibitorforthetreatmentofhemolyticanemiaduetosicklecelldisease AT sharifj 5613294baselinepatientcharacteristicsfromaukearlyaccesstomedicinesschemeeamswithvoxelotorahbspolymerizationinhibitorforthetreatmentofhemolyticanemiaduetosicklecelldisease AT kesseadur 5613294baselinepatientcharacteristicsfromaukearlyaccesstomedicinesschemeeamswithvoxelotorahbspolymerizationinhibitorforthetreatmentofhemolyticanemiaduetosicklecelldisease AT filiangloorm 5613294baselinepatientcharacteristicsfromaukearlyaccesstomedicinesschemeeamswithvoxelotorahbspolymerizationinhibitorforthetreatmentofhemolyticanemiaduetosicklecelldisease AT agrawala 5613294baselinepatientcharacteristicsfromaukearlyaccesstomedicinesschemeeamswithvoxelotorahbspolymerizationinhibitorforthetreatmentofhemolyticanemiaduetosicklecelldisease AT barcelosg 5613294baselinepatientcharacteristicsfromaukearlyaccesstomedicinesschemeeamswithvoxelotorahbspolymerizationinhibitorforthetreatmentofhemolyticanemiaduetosicklecelldisease AT telferp 5613294baselinepatientcharacteristicsfromaukearlyaccesstomedicinesschemeeamswithvoxelotorahbspolymerizationinhibitorforthetreatmentofhemolyticanemiaduetosicklecelldisease |